CO2017001226A2 - Derivados de 6–alquinil–piridina como miméticos de smac - Google Patents
Derivados de 6–alquinil–piridina como miméticos de smacInfo
- Publication number
- CO2017001226A2 CO2017001226A2 CONC2017/0001226A CO2017001226A CO2017001226A2 CO 2017001226 A2 CO2017001226 A2 CO 2017001226A2 CO 2017001226 A CO2017001226 A CO 2017001226A CO 2017001226 A2 CO2017001226 A2 CO 2017001226A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkynyl
- smac mimetics
- pyridine derivatives
- pyridine
- smac
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a 6–alquinil–piridina de la fórmula general (I) su uso como miméticos de SMAC, composiciones farmacéuticas que los contienen y su uso como un medicamento para el tratamiento y/o la prevención de enfermedades caracterizadas por la proliferación celular excesiva o anormal y condiciones asociadas como cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14180554 | 2014-08-11 | ||
PCT/EP2015/068349 WO2016023858A1 (en) | 2014-08-11 | 2015-08-10 | 6-alkynyl-pyridine derivatives as smac mimetics |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017001226A2 true CO2017001226A2 (es) | 2017-05-10 |
Family
ID=51300621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0001226A CO2017001226A2 (es) | 2014-08-11 | 2017-02-08 | Derivados de 6–alquinil–piridina como miméticos de smac |
Country Status (34)
Country | Link |
---|---|
US (4) | US9481673B2 (es) |
EP (1) | EP3180339B1 (es) |
JP (1) | JP6250226B2 (es) |
KR (1) | KR102445744B1 (es) |
CN (2) | CN111440164B (es) |
AP (1) | AP2017009718A0 (es) |
AR (1) | AR101479A1 (es) |
AU (1) | AU2015303308B2 (es) |
BR (1) | BR112017002498B1 (es) |
CA (1) | CA2956123C (es) |
CL (1) | CL2017000326A1 (es) |
CO (1) | CO2017001226A2 (es) |
CY (1) | CY1121273T1 (es) |
DK (1) | DK3180339T3 (es) |
EA (1) | EA031424B1 (es) |
ES (1) | ES2711763T3 (es) |
HR (1) | HRP20190336T1 (es) |
HU (1) | HUE043915T2 (es) |
IL (1) | IL249844B (es) |
LT (1) | LT3180339T (es) |
ME (1) | ME03303B (es) |
MX (1) | MX2017001835A (es) |
NZ (1) | NZ728073A (es) |
PE (1) | PE20170193A1 (es) |
PH (1) | PH12017500231A1 (es) |
PL (1) | PL3180339T3 (es) |
PT (1) | PT3180339T (es) |
RS (1) | RS58355B1 (es) |
SG (1) | SG11201700999YA (es) |
SI (1) | SI3180339T1 (es) |
TR (1) | TR201902023T4 (es) |
TW (1) | TWI723959B (es) |
UA (1) | UA118887C2 (es) |
WO (1) | WO2016023858A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR101479A1 (es) * | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
EA038950B1 (ru) * | 2016-05-19 | 2021-11-12 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения производных 6-алкинил-пиридина |
MX2019011572A (es) * | 2017-03-31 | 2019-11-18 | Boehringer Ingelheim Int | Tratamiento conjunto antineoplasico. |
CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
TW202043466A (zh) | 2019-01-25 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
BR112022005624A2 (pt) | 2019-09-25 | 2022-07-12 | Debiopharm Int Sa | Regimes de dosagem para tratamento de pacientes com carcinoma de células escamosas localmente avançado |
EP4161544A1 (en) | 2020-06-03 | 2023-04-12 | Boehringer Ingelheim International GmbH | Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
RU2007147959A (ru) | 2005-06-08 | 2009-07-20 | Новартис АГ (CH) | Органические соединения |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
CN101595093A (zh) * | 2006-12-07 | 2009-12-02 | 诺瓦提斯公司 | 有机化合物 |
US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
AR101479A1 (es) * | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
-
2015
- 2015-08-07 AR ARP150102551A patent/AR101479A1/es unknown
- 2015-08-10 CN CN201911357061.2A patent/CN111440164B/zh active Active
- 2015-08-10 NZ NZ728073A patent/NZ728073A/en unknown
- 2015-08-10 RS RS20190219A patent/RS58355B1/sr unknown
- 2015-08-10 ME MEP-2019-29A patent/ME03303B/me unknown
- 2015-08-10 DK DK15747820.7T patent/DK3180339T3/en active
- 2015-08-10 CN CN201580039248.1A patent/CN106573930B/zh active Active
- 2015-08-10 KR KR1020177005822A patent/KR102445744B1/ko active IP Right Grant
- 2015-08-10 BR BR112017002498-5A patent/BR112017002498B1/pt active IP Right Grant
- 2015-08-10 SG SG11201700999YA patent/SG11201700999YA/en unknown
- 2015-08-10 HU HUE15747820A patent/HUE043915T2/hu unknown
- 2015-08-10 CA CA2956123A patent/CA2956123C/en active Active
- 2015-08-10 TW TW104125989A patent/TWI723959B/zh active
- 2015-08-10 JP JP2017507775A patent/JP6250226B2/ja active Active
- 2015-08-10 MX MX2017001835A patent/MX2017001835A/es active IP Right Grant
- 2015-08-10 TR TR2019/02023T patent/TR201902023T4/tr unknown
- 2015-08-10 US US14/821,870 patent/US9481673B2/en active Active
- 2015-08-10 AU AU2015303308A patent/AU2015303308B2/en active Active
- 2015-08-10 LT LTEP15747820.7T patent/LT3180339T/lt unknown
- 2015-08-10 PL PL15747820T patent/PL3180339T3/pl unknown
- 2015-08-10 AP AP2017009718A patent/AP2017009718A0/en unknown
- 2015-08-10 PE PE2017000209A patent/PE20170193A1/es unknown
- 2015-08-10 SI SI201530611T patent/SI3180339T1/sl unknown
- 2015-08-10 EA EA201790349A patent/EA031424B1/ru not_active IP Right Cessation
- 2015-08-10 EP EP15747820.7A patent/EP3180339B1/en active Active
- 2015-08-10 WO PCT/EP2015/068349 patent/WO2016023858A1/en active Application Filing
- 2015-08-10 ES ES15747820T patent/ES2711763T3/es active Active
- 2015-08-10 PT PT15747820T patent/PT3180339T/pt unknown
- 2015-10-08 UA UAA201702213A patent/UA118887C2/uk unknown
-
2016
- 2016-10-03 US US15/283,494 patent/US9801871B2/en active Active
- 2016-12-29 IL IL249844A patent/IL249844B/en active IP Right Grant
-
2017
- 2017-02-08 CO CONC2017/0001226A patent/CO2017001226A2/es unknown
- 2017-02-08 PH PH12017500231A patent/PH12017500231A1/en unknown
- 2017-02-08 CL CL2017000326A patent/CL2017000326A1/es unknown
- 2017-09-26 US US15/715,351 patent/US10413536B2/en active Active
-
2019
- 2019-02-19 CY CY20191100213T patent/CY1121273T1/el unknown
- 2019-02-20 HR HRP20190336TT patent/HRP20190336T1/hr unknown
- 2019-08-02 US US16/530,084 patent/US20190358218A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CO2017001226A2 (es) | Derivados de 6–alquinil–piridina como miméticos de smac | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
CL2014002257A1 (es) | Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer. | |
BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
UY35711A (es) | Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
UY35710A (es) | 6-alquinilpiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
CL2018000783A1 (es) | Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
MX2017007377A (es) | Compuestos organicos. | |
ECSP14014778A (es) | Composiciones derivadas de la quitosana | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
MX371158B (es) | Compuestos inhibidores de pde2. | |
DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
UY35600A (es) | "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas" | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |